Bottom line
Is SUHIX a good fund? The bottom line
SUHIX is the Institutional Class share class of DWS Health and Wellness Fund, an actively managed health care sector mutual fund from DWS (Xtrackers).
It charges 1.04% — about $104 a year on every $10,000 invested, more expensive than 56% of health care sector funds we track.
With $232 million in net assets and 65 holdings, its largest position is Eli Lilly & Co (13.9%) and the top 10 make up 51.3% of the portfolio.
The closest lower-cost alternative we found is XLV (0.08%, 81% top-holdings overlap).
What stands out
- No front-end sales load
What to watch
- Concentrated: top 10 holdings are 51.3% of assets
Updated Nov 19, 2026
What SUHIX invests in
The fund seeks long-term growth of capital.
Main investments. Under normal circumstances, the fund invests at least 80% of net assets, plus the amount of any borrowings for investment purposes, in equity securities of companies in the health care and wellness sectors. For purposes of the funds 80% investment policy, to be considered part of the health care or wellness sectors, companies must commit at least half of their assets to, or derive at least half of their revenues or net income from, that sector. Industries in the health care sector include pharmaceuticals, biotechnology, medical products and supplies, and health care services. Portfolio management considers wellness-related companies to include companies in the health care industry and other companies that provide products or services that promote or aid in achieving a healthy lifestyle (for example, healthy food and nutrition companies and gym operators). The fund…
From the fund's prospectus (filed Sep 24, 2026).
What SUHIX costs
On a $10,000 investment, SUHIX's 1.04% expense ratio costs about $104 a year. The prospectus estimates $1,303 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
SUHIX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co | 13.85% |
| 2 | Johnson & Johnson | 6.19% |
| 3 | UnitedHealth Group Inc | 5.73% |
| 4 | AbbVie Inc | 4.90% |
| 5 | Merck & Co Inc | 4.85% |
| 6 | AstraZeneca PLC | 3.80% |
| 7 | Thermo Fisher Scientific Inc | 3.46% |
| 8 | Novartis AG | 2.90% |
| 9 | Amgen Inc | 2.88% |
| 10 | Gilead Sciences Inc | 2.78% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 51.3% of the fund. See all top 25 holdings and asset mix →
Alternatives to SUHIX
| Family | Fund | Expense ratio | Overlap | |
|---|---|---|---|---|
| SPDR (State Street) | XLV State Street(R) Health Care Select… | 0.08% | 81% | Compare |
| Fidelity | FHLC Fidelity MSCI Health Care Index ETF | 0.084% | 81% | Compare |
| Vanguard | VHT Vanguard Health Care Index Fund | 0.09% | 79% | Compare |
| iShares | IYH iShares U.S. Healthcare ETF | 0.37% | 76% | Compare |
| J.P. Morgan | JDOC JPMorgan Healthcare Leaders ETF | 0.65% | 65% | Compare |
| Schwab | SWHFX Schwab Health Care Fund | 0.8% | 71% | Compare |